Media Articles Related to Ifex (Ifosfamide)
Source: MedicineNet Cancer Causes Specialty [2016.11.28]
Title: Testicular Cancer
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 11/28/2016 12:00:00 AM
IU study finds testicular cancer survivors may have hearing loss after cisplatin therapy
Source: Hearing / Deafness News From Medical News Today [2016.06.28]
Many testicular cancer survivors experience hearing loss after cisplatin-based chemotherapy, according to researchers at Indiana University.The researchers, led by Lois B. Travis, M.D., Sc.D.
New pharmacon allows testicular tumors to shrink
Source: Cancer / Oncology News From Medical News Today [2017.01.04]
A new active pharmaceutical ingredient may help against severe forms of testicular cancer, which only respond inadequately to other therapies.
Published Studies Related to Ifex (Ifosfamide)
A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). [2011.05]
CONCLUSION: This study could not demonstrate that high-dose chemotherapy given as part of first-line therapy improves outcome in patients with poor-prognosis GCC.
Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma. [2009.10]
Multidrug chemotherapy increases responses in advanced soft tissues sarcoma. Can a 20% increase of relative dose intensity of the MAID regimen, more improve responses? From 1994 to 1997, 162 patients were randomized in a phase III study to the conventional drug combination (6 cycles of MAID: 60, 7,500, 900 mg/m(2) for doxorubicin, ifosfamide and dacarbazine respectively), or at doses 20-33% higher per cycle (5 cycles of intensified MAID for similar cumulative doses) with systematic G-CSF...
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. [2009.09.01]
PURPOSE: To evaluate the safety and efficacy of trabectedin in a phase II, open-label, multicenter, randomized study in adult patients with unresectable/metastatic liposarcoma or leiomyosarcoma after failure of prior conventional chemotherapy including anthracyclines and ifosfamide... CONCLUSION: Prior studies showed clinical benefit with trabectedin in patients with sarcomas after failure of standard chemotherapy. This trial documents superior disease control with the q3 weeks 24-hour trabectedin regimen in liposarcomas and leiomyosarcomas, although the qwk 3-hour regimen also demonstrated activity relative to historical comparisons. Trabectedin may now be considered an important new option to control advanced sarcomas in patients after failure of available standard-of-care therapies.
Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study. [2009.08]
BACKGROUND: We undertook a randomized phase II trial to test whether the addition of paclitaxel (Taxol) to the cisplatin and ifosfamide (IP) combination could improve objective response (OR) rate, progression-free survival (PFS) and overall survival (OS) in patients with recurrent or metastatic cancer of the uterine cervix... CONCLUSION: The ITP combination merits further investigation in randomized phase III studies.
Chemotherapy: The role of ifosfamide and etoposide in Ewing sarcoma. [2009.05]
The EICESS-92 Trial compared the efficacy of cyclophosphamide and ifosfamide in patients with Ewing sarcoma. Subgroup analysis suggested that patients with large, localized tumors benefited from the addition of etoposide, whereas patients with metastases did not..
Clinical Trials Related to Ifex (Ifosfamide)
Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors [Active, not recruiting]
This is an open-label study of palifosfamide-tris administered intravenously on Days 1, 2,
and 3 of a 21-day cycle to subjects with advanced solid tumors. Enrolled subjects will
receive a placebo-control infusion on Day - 1 and then commence palifosfamide-tris study
treatment 24 hours later on Day 1.
Time-matched, intensive ECG monitoring will occur during and following placebo and
palifosfamide-tris infusions on Days - 1, 1, 2, 3 and 8. Generation of ECG data for study
analysis will be performed in a blinded fashion at a central ECG laboratory.
Blood and urine sampling to characterize the pharmacokinetics of palifosfamide-tris will be
performed on Days 1 through 8 of Cycle 1.
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma [Recruiting]
This phase I/II trial studies the side effects and best dose of brentuximab vedotin that can
be combined with ifosfamide, carboplatin, and etoposide in treating patients with Hodgkin
lymphoma that has come back (relapsed) or is not responding to treatment (refractory).
Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in
different ways by targeting certain cells. Drugs used in chemotherapy, such as ifosfamide,
carboplatin, and etoposide, work in different ways to stop the growth of cancer cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving brentuximab vedotin together with an ifosfamide, carboplatin, and
etoposide chemotherapy regimen may kill more cancer cells.
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen [Active, not recruiting]
The goal of this clinical research study is to learn how different doses of fosaprepitant
may effect how ifosfamide-based chemotherapy is absorbed by the body. Researchers also want
to learn if fosaprepitant can help to control or prevent delayed nausea and/or vomiting that
may be caused by chemotherapy. The safety of this drug will also be studied.
Fosaprepitant is designed to block the natural substance in the brain that causes nausea and
vomiting. This may help to prevent and/or control nausea and vomiting caused by
Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors [Completed]
- To determine the maximum tolerated dose (MTD) of Topotecan when added to a fixed dose
regimen of Ifosfamide and Carboplatin in children and young adults with solid tumors.
- To evaluate the toxicity associated with the administration of Topotecan with
Ifosfamide and Carboplatin (TIC) in children and young adults with solid tumors.
- To evaluate the duration of neutropenia (ANC<500/micro L) and thrombocytopenia (PLT
50,000/ micro L and 20,000/ micro L) and the number of days of platelet transfusion
during each course of TIC chemotherapy when used in conjunction with G-CSF and NEUMEGA
in children and young adults with solid tumors.
- To determine the median number of apheresis collections as well as the CD34/kg,
CD41/kg, CD61/kg and CD34: 41/kg and CD34: 61/kg per collection in patients electively
undergoing concurrent apheresis for peripheral blood stem cell collection in courses 2
- To determine the median number of peripheral blood mononuclear cells (PBMC) and ex-vivo
expanded myeloid dendritic cells (DC) in patients electively undergoing concurrent
apheresis for PBMC collection in courses 2 or 3.
Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors [Terminated]
This randomized phase I trial is studying the side effects and best dose of
O(6)-benzylguanine when given together with ifosfamide and to see how well it works compared
to ifosfamide alone in treating patients with unresectable metastatic solid tumors. Drugs
used in chemotherapy, such as ifosfamide and O(6)-benzylguanine, work in different ways to
stop tumor cells from dividing so they stop growing or die. Combining ifosfamide with
O(6)-benzylguanine may kill more tumor cells